

Special Issue

Pathogenesis and Counteracting Strategies of Hepatocellular Carcinoma, Cholangiocarcinoma and Urothelial Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma, cholangiocarcinoma and urothelial carcinoma are aggressive cancers causing morbidity, mortality and health burden worldwide. Hepatocellular carcinoma is mostly caused by chronic viral infections, while the etiology of cholangiocarcinoma and urothelial carcinoma are only partly known so far. The pathogenesis of these cancers awaits more research in order to be fully elucidated. Novel therapeutic targets and treatment strategies may arise from the investigations of the pathogenic mechanisms. Immunotherapies are becoming more and more important in treating all cancers with the advancement of knowledge about tumor-immune system interactions. The stratification of patients with respect to their distinct pathogenic mechanisms and estimated outcomes are helpful for guiding personally optimized treatments. We hereby solicit academic manuscripts regarding pathogenesis and counteracting strategies for hepatocellular carcinoma, cholangiocarcinoma and urothelial carcinoma to be considered for publication in this Special Issue of *Biomedicines*.

Guest Editor

Prof. Dr. Kung-Hao Liang

1. Department of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan
2. Institute of Biomedical Informatics, National Yang Ming Chiao Tung University, Taipei 112, Taiwan
3. Institute of Food Safety and Health Risk Assessment, National Yang Ming Chiao Tung University, Taipei 112, Taiwan

Deadline for manuscript submissions

closed (15 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/101789

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).